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Abstract Calciﬁcation is a major factor that limits the dur-
ability of bioprosthetic valve. A novel bovine pericardial
tissue treated with aldehyde capping chemistry and glycer-
olization was evaluated for its resistance to calciﬁcation in
comparison with porcine tissues treated with amino oleic
acid and bovine pericardial tissue with ethanol rinsing in a
rabbit intramuscular model. Tissue discs from the test and
control tissues were implanted in rabbits for 60 days. The
explanted discs were subject to X-ray imaging, calcium
quantiﬁcation and histology analysis. The test tissue showed
95 and 96% reduction in calciﬁcation in comparison with
amino oleic acid treatment and ethanol rinsing treatment,
respectively. In addition, the test tissue showed the least
inﬂammatory response as evidenced by a reduced amount of
macrophages and giant cells in histology analysis. Further-
more, the aldehyde analysis of the pre-implanted samples
showed associated reduction in free aldehyde levels with the
test tissue. The reduction in calciﬁcation is consistent with
previously reported results and is hypothesized to be attrib-
uted to the capping of free aldehydes in the test tissue.
1 Introduction
Bioprosthetic heart valves have been widely used to replace
diseased native valves. Tissue valves, constructed either from
porcine aortic valves or from bovine pericardium, have
become favored over mechanical valves due to their bio-
compatibility, hemodynamic superiority and the elimination of
the need for life-long anti-coagulant regimens. However, the
durability of tissue valves is limited by the progressive
structural deterioration primarily due to calciﬁcation [1–3].
There are a number of mechanisms underlying tissue
calciﬁcation including the presence of residual phospholi-
pids and residual free aldehyde functional groups due to
glutaraldehyde ﬁxation in tissue preparations, which can be
directly correlated to bioprosthetic tissue calciﬁcation [4–8].
Therefore, a number of technologies have been developed
aimed at mitigating calciﬁcation that target these sources
using various approaches. Most anti-calciﬁcation technolo-
gies involve the reduction of phospholipids through the use
of various detergents. This approach has proven effective in
inhibiting calciﬁcation as evidenced by numerous in vivo
studies [9–12]. Effective targeting of free aldehydes within
the tissue, however, has been more challenging, as most
currently available tissue valves rely on the use of glutar-
aldehyde both during the glutaraldehyde cross-linking pro-
cess as well as their long-term storage within
glutaraldehyde-based preservatives, both sources for the
development of free aldehydes. Consequently, the few
commercially available technologies targeting free alde-
hydes have inherent limitations providing long-term pro-
tection against calciﬁcation via these free aldehydes, as
evidenced by the current literature [13, 14].
The limitations inherent within current technologies
prompted the development of a novel method of targeting free
aldehydes. An aldehyde capping chemistry was developed to
covalently cap free aldehydes within bovine pericardial tissue
through chemical reduction while preventing tissue from
further exposure to glutaraldehyde solutions by glyceroliza-
tion so that the tissue can be stored dry without a liquid
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sterilant. The aim of this study was to evaluate the reduction
in calciﬁcation using this new pericardial tissue in comparison
with two commercial tissues containing anti-calciﬁcation
technologies.
2 Materials and methods
2.1 Tissue sample preparation
The test tissue was generated by following a previously
described method [15]. In brief, the glutaraldehyde- treated
bovine pericardium tissue was treated with an amine and
reducing compound to block the residual aldehyde groups.
Fig. 1 Box and Whisker plot of calcium contents of explanted tissue
discs
Table 1 Summary of calcium content in the explanted samples (mg/g)
Tissue n Mean± StDev 25%, 50%, 75%
quantile
Test 62 29.62± 43.84 0.12, 5.08,
40.15
Porcine with AOA 62 97.62± 74.63 2.66, 96.6, 163
Bovine pericardium with
Linx
62 117.26± 63.1 82.35, 141, 155
Glutaraldehyde only 62 180.86± 29.78 168, 184, 195
Fig. 2 Representative X-ray
images of tissue discs after
explant of test group (a), porcine
tissue treated with AOA (b),
bovine pericardial tissue treated
with Linx (c) and bovine
pericardial tissue treated with
glutaraldehyde only (d). The
white area represents the
calciﬁed nodule. The X-ray
images were sorted based on the
calcium content and the median
calcium images were selected as
representative
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It was followed by glycerolization, which preserved the
tissue for dry storage without the need of an aldehyde-
containing sterilant. The control samples were harvested
from commercially available tissue valves which included:
porcine tissue treated with 2-amino oleic acid (AOA) anti-
calciﬁcation technology (Medtronic, Minneapolis, MN) and
bovine pericardial tissue treated with Linx anti-calciﬁcation
technology (St Jude Medical, St Paul, MN). A 6 mm sterile
biopsy punch was used to harvest 4–6 samples per valve
leaﬂet in an aseptic environment. Bovine pericardial tissue
ﬁxed in glutaraldehyde with no other treatment was used as
positive control.
2.2 Animal implantation
This study was approved in advance by the institutional
animal care and use committee at Edwards Lifesciences
and was performed in an AAALAC-accredited facility.
6–8 week old New Zealand White rabbits (n = 64) were
acquired from Western Oregon Rabbitry (Philomath, OR).
Rabbits were housed individually or in pairs, depending on
their size. The rabbits were allowed to acclimate for at
least 6 days after receipt. Before their use in the study, the
rabbits’ health was evaluated by either a trained animal
care technician or the attending veterinarian. The rabbits
were fed a high-ﬁber commercial diet (LabDiet 5325,
Newco Distributors, Ranch Cucamonga, CA) once daily
and received water through an automatic watering system
ad libitum. The rabbit room was maintained at 16.7–22.2 °
C on a 12 : 12-h photoperiod, and humidity was kept
between 30 and 70 % with a minimum of 12–15 air
changes per hour.
Tissue samples were implanted intramuscularly into
rabbits according to the previously published methodology
[16]. The intramuscular rabbit model has proven to be a
fast and aggressive differentiator of anti-calciﬁcation
treatment [16, 17]. Each rabbit received one disc from
each sample group and the position of the discs was ran-
domized. The rabbits were monitored for pain and dis-
comfort post-operatively. All 64 rabbits survived the
implantation and monitoring duration. The discs were
retrieved at 60 days after implantation. The discs from two
rabbits were explanted with surrounding muscle for his-
tological evaluation. The remainder of the discs were
subjected to calcium analysis following host tissue
removal. All discs were immediately stored in 10 % buf-
fered formalin upon explant.
2.3 Histological examination
The explanted discs from two randomly selected rabbits
were subject to histology examination. Discs were embed-
ded in parafﬁn and stained with Hematoxylin and eosin
(H&E) and von Kossa stain for histological analysis at
IDEXX Laboratories (Sacramento, CA). The slides were
examined by a blinded investigator under microscope at
25× and 400× magniﬁcation for calciﬁcation, collagen
degradation, host cell inﬁltration, and inﬂammatory
responses. The number of macrophages and giant cells were
counted along the periphery of two sets of tissue samples.
2.4 Tissue calciﬁcation analysis
The calciﬁcation levels in each disc were qualitatively
evaluated by X-ray imaging prior to lyophilization and
digested in nitric acid. Calcium levels were quantiﬁed by an
independent analytical laboratory (Exova, Santa Fe Springs,
CA) using ICP-OES (Thermo Fisher Scientiﬁc, Waltham,
MA). Elemental concentrations were reported as milligram
of calcium per gram of lyophilized tissue.
Table 2 p-value of the calcium
comparison between the
different tissue treatments
Porcine with AOA Bovine pericardium with Linx Glutaraldehyde only
Test <0.01 <0.01 <0.01
Porcine with AOA – 0.17 <0.01
Bovine pericardium with Linx – – <0.01
Fig. 3 Free aldehyde content of pre-implanted tissue. Ten samples
were measured for each group
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2.5 Aldehyde analysis
The quantiﬁcation of free aldehyde in the tissue sample was
performed as reported previously [18]. A 6 mm tissue disc
was punched from each leaﬂet and was subjected to the
aldehyde analysis. A total of ten discs were measured for
each tissue sample. The results were expressed as nano-
mole aldehyde per disc.
3 Results
3.1 Calciﬁcation analysis
The quantitative analysis of the calcium are presented in Fig. 1
and Table 1. The large variance of the data, which is typical
for animal studies, can be attributed to the variation of the
sample and the individual animals. Due to the skewness of the
Muscle 
Tissue sample
Fig. 4 Representative H&E
images of test (a), porcine tissue
with AOA (b), bovine
pericardium with Linx (c) and
glutaraldehyde only tissue (d)
tissue after 60 day implant. The
left images are 25× and the right
images are 400×. The blue dots
are the giant cells and
macrophages
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data, Mann-Whitney method was used to compare the median
between the groups. The results show the tissues treated with
anti-calciﬁcation technologies reduced calciﬁcation to various
degrees over the glutaraldehyde only tissue, with a 23%
reduction for Linx- treated bovine pericardium, 48% for
AOA- treated porcine, and 97% for the test tissue. In addition,
the test tissue showed signiﬁcantly (p< 0.05, Table 2) lower
measured calcium content than both Linx- treated tissue and
porcine tissue treated with AOA, demonstrating 96 and 95%
reductions, respectively. No signiﬁcant difference was evident
between the AOA and Linx tissue samples.
The calciﬁcation nodules are readily visible on the
representative X-ray images (Fig. 2). The visual observation
shows the lowest calciﬁcation for the test tissue, which is
consistent with the quantitative analysis.
3.2 Aldehyde analysis
The free aldehyde content in each tissue was measured
(Fig. 3). It is expected that the tissue samples have residual
aldehyde due to the glutaraldehyde ﬁxation even after
treatment to block the aldehyde groups. The test tissue
showed the least amount of free aldehyde among the sample
groups. The aldehyde in test tissue was 33.3 and 36.8 % less
than AOA- treated and Linx- treated tissue, respectively. In
addition, the test group had less variation than the Linx and
AOA- treated tissues.
3.3 Histological analysis
The overall biocompatibility and calciﬁcation of the implants
were determined by histological analysis using H&E and von
Kossa stains with focus on the inﬂammatory response, tissue
degeneration, and calciﬁcation. All the samples showed the
typical calciﬁcation and foreign body response, such as
inﬂammatory response, but to different degrees. The samples
with anti-calciﬁcation treatment showed well preserved col-
lagen structure, while the collagen in the glutaraldehyde-
only group was largely calciﬁed; this indicates that the
anti-calciﬁcation treatments are effective in reducing the
calciﬁcation level and preserving the collagen structure. As
shown in the representative histological images from each
experimental group, in contrast to the control samples, the
test tissue elicited less of an inﬂammatory response through a
visible reduction in macrophage and foreign body reaction
giant cell inﬁltrates (Fig. 4). The counts of macrophages and
giant cells from the test and control groups conﬁrmed this
observation (Table 3). The AOA- treated tissue showed the
most severe chronic inﬂammatory response among the
groups with anti-calciﬁcation treatment. No apparent calci-
ﬁcation was visible in the representative test tissue explants
while tissue calciﬁcation was observed in all of the control
groups by von Kossa stain (Fig. 5). These ﬁndings are con-
sistent with the calciﬁcation analysis and X-ray radiography.
4 Discussion
Calciﬁcation has been the major failure mode for tissue
heart valves since their introduction in the 1960s. Improved
tissue processing, valve design and application of anti-
calciﬁcation technologies have contributed to improved
durability. However, even with these advancements current
expected tissue valve longevity is less than the average life
expectancy of patients undergoing aortic valve replacement
[19]. Since life expectancy continues to rise in aging
populations, there is a critical need to provide a more dur-
able tissue valve, especially one that can mitigate calciﬁ-
cation. This newly developed tissue targeting calciﬁcation is
intended to address this unmet need.
Previously reported results on the safety and efﬁcacy of
this new tissue in small animal and large animal studies
demonstrate signiﬁcant improvements in resistance to cal-
ciﬁcation compared to contemporary valve tissues. The test
tissue showed more than 90 % reduction in calciﬁcation in
comparison with Edwards ThermaFix tissue in a rabbit
model similar to the one used in the current study [18]. In
both studies, the test tissue consistently showed low levels
of calciﬁcation (median calcium 6.8 mg/g in the previous
study and 5.08 mg/g in the current study). Most notably,
Flameng et al. demonstrated statistically signiﬁcant
improvements in hemodynamic performance in valves with
the test tissue over standard treated bovine pericardium [15].
While these preclinical studies used Edwards Lifesciences
Table 3 The number of
macrophage and giant cell
counts for each tissue
Macrophage Giant cell
Rabbit 1 Rabbit 2 Average Rabbit 1 Rabbit 2 Average
Test 65 89 77 27 26 27
Porcine with AOA 101 329 215 83 211 147
Bovine pericardium with Linx 124 133 129 74 80 77
Glutaraldehyde only 168 227 198 115 160 138
An average of ten images were captured around the tissue sample and the total number of macrophage and
giant cells from the images were counted
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standard bovine pericardial tissue and valves as controls, the
current study utilizes other commercial tissue samples as
comparators to assess this novel tissue’s efﬁcacy against
technologies that employ similar techniques for reducing
residual aldehyde groups and phospholipids.
The calciﬁcation results conﬁrmed previous study outcomes
and showed a signiﬁcant reduction of calcium content in the test
group. The glutaraldehyde only group (positive control) was
heavily calciﬁed as expected. The median calcium content of
the test tissue group (5.08mg/g) showed signiﬁcant reduction in
calcium content in comparison with AOA (96mg/g) and Linx
(141mg/g) treated tissue groups. The test tissue data points
were highly concentrated at the low calcium range and had a
long positive tail while the other groups were more normally
distributed. The long positive tail on the box and whisker may
be attributed to the variation of the animal response.
Muscle 
Tissue sample
Fig. 5 Representative von
Kossa images of test (a), porcine
tissue with AOA (b), bovine
pericardium with Linx (c) and
glutaraldehyde only tissue (d)
tissue after 60 day implant. The
left images are 25× and the right
images are 400×. The brown
color is the calciﬁed sites
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A correlation between aldehyde content and calciﬁcation
has been established in a previous study, in which peri-
cardial tissue prepared by Edwards was investigated [18]. In
the current study, the calciﬁcation level also correlates with
the aldehyde content reduction across the test tissue and the
two controls. The observation suggests that free aldehyde
may solicit a host response to trigger calciﬁcation, which is
consistent with the previous studies [20].
Histological examination of all sample groups demon-
strated a typical inﬂammatory response. The test tissue
demonstrated the lowest amount of inﬂammatory inﬁltration
as evidenced by decreased amounts of giant cells and
macrophages in the surrounding host tissue. The collagen
structure of the test tissue was well preserved without visible
calciﬁcation sites, as identiﬁed by von Kossa stain. The
AOA, Linx and glutaraldehyde-only tissues elicited
increased levels of inﬂammatory response, especially around
the calciﬁcation sites. These results suggest that valves with
this newly developed tissue may offer improved durability,
addressing this important unmet need for patients [19].
5 Conclusions
The study demonstrates that this novel tissue can reduce
calciﬁcation by 95 % in comparison with commercially
available tissues in the intramuscular rabbit model. The
reduction in calciﬁcation is consistent with previously
reported results, and it is hypothesized that it is attributed to
stable capping of free aldehydes and the ability to be stored
dry without aldehyde based sterilant. Further studies will be
needed to establish the relationship between improved pre-
clinical effectiveness and clinical outcomes.
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